This clinical trial is focused on studying a type of blood cancer called chronic myeloid leukemia (CML), specifically in its chronic phase. The treatment being tested is a medication called Ponatinib, which is taken as a film-coated tablet. Ponatinib is a type of drug known as a tyrosine kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to assess patients who have achieved a specific level of response, known as MR4, after two years of treatment with Ponatinib. MR4 is a term used to describe a deep molecular response, indicating a very low level of cancer cells in the body. The study will follow participants over a period of 24 months to monitor their response to the treatment. During this time, researchers will evaluate the molecular status of the disease, the safety and tolerability of Ponatinib, and any side effects that may occur. Additionally, the study will look at the quality of life of participants while on the treatment.

Throughout the study, researchers will also identify factors that may be associated with achieving MR4 or better, such as risk scores and the duration of previous treatments. The study aims to provide insights into the potential for treatment-free remission, where patients may be able to stop treatment while maintaining their response. Overall survival and progression-free survival will also be evaluated to understand the long-term benefits of Ponatinib therapy.